UBS Group’s Universe Pharmaceuticals Inc UPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $6.66K | Sell |
1,550
-12,817
| -89% | -$62.9K | ﹤0.01% | 9389 |
|
|
2026
Q2 | $87.6K | Buy |
+14,367
| New | +$46.7K | ﹤0.01% | 7261 |
|
|
2026
Q1 | – | Sell |
-946
| Closed | -$3.6K | – | 11196 |
|
|
2025
Q4 | $3.6K | Buy |
946
+945
| +94,500% | +$4.21K | ﹤0.01% | 8985 |
|
|
2025
Q3 | $4 | Buy |
+1
| New | +$4 | ﹤0.01% | 10242 |
|
|
2025
Q2 | – | Sell |
-266
| Closed | -$1.09K | – | 10852 |
|
|
2025
Q1 | $1.09K | Buy |
+266
| New | +$2.95K | ﹤0.01% | 9579 |
|
|
2024
Q4 | – | Sell |
-404
| Closed | -$59.2K | – | 10421 |
|
|
2024
Q3 | $59.2K | Buy |
404
+395
| +4,389% | +$672K | ﹤0.01% | 6708 |
|
|
2024
Q2 | $13K | Buy |
9
+7
| +350% | +$9.7K | ﹤0.01% | 7571 |
|
|
2024
Q1 | $2.38K | Buy |
+2
| New | +$2.26K | ﹤0.01% | 7913 |
|
|
2023
Q4 | – | Sell |
-1
| Closed | -$808 | – | 9908 |
|
|
2023
Q3 | $808 | Buy |
+1
| New | +$1.01K | ﹤0.01% | 8264 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$6.67K | – | 10411 |
|
|
2022
Q4 | $6.67K | Sell |
1
-2
| -67% | -$9.27K | ﹤0.01% | 9003 |
|
|
2022
Q3 | $5K | Buy |
+3
| New | +$6.49K | ﹤0.01% | 9232 |
|
|
2022
Q2 | – | Hold |
0
| – | -$1K | – | 10974 |
|
|
2022
Q1 | – | Sell |
-2
| Closed | -$10.1K | – | 9935 |
|
|
2021
Q4 | $11K | Buy |
+2
| New | +$15.4K | ﹤0.01% | 8697 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 8844 |
|
|
2021
Q2 | – | Sell |
-10
| Closed | -$125K | – | 8842 |
|
|
2021
Q1 | $140K | Buy |
+10
| New | +$160K | ﹤0.01% | 5710 |
|
Other funds holding UPC
UBS Group's UPC Position: Q3 2026 in Review
UBS Group reduced its Universe Pharmaceuticals Inc (UPC) stake by 89% in Q3 2026, selling an estimated $62.9K and leaving 1,550 shares worth $6.66K. The position accounts for ﹤0.01% of the portfolio, ranked #9389.
UBS Group first reported a position in UPC in Q1 2021 and has held it in 13 quarters since. The position peaked at $140K in Q1 2021. 3 funds tracked by Wall St. Rank hold UPC as of Q3 2026.
- UBS Group held 1,550 shares of Universe Pharmaceuticals Inc worth $6.66K as of Q3 2026.
- UBS Group sold 12,817 Universe Pharmaceuticals Inc shares in Q3 2026, an estimated $62.9K.
- Universe Pharmaceuticals Inc made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9389 holding.
- UBS Group first reported a position in Universe Pharmaceuticals Inc in Q1 2021 and has held it in 13 quarters since.
- UBS Group's Universe Pharmaceuticals Inc position peaked at $140K in Q1 2021.
- 3 funds tracked by Wall St. Rank held Universe Pharmaceuticals Inc as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.